Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 as a Single Agent and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Conditions
Interventions
LYT-200
Tislelizumab
+1 more
Locations
12
United States
UCLA
Los Angeles, California, United States
University of Colorado Hospital
Denver, Colorado, United States
Sarah Cannon Research Institute at Health One
Denver, Colorado, United States
Sarah Cannon Research Institute, Florida Cancer Specialists
Sarasota, Florida, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Start Date
December 15, 2020
Primary Completion Date
December 12, 2024
Completion Date
December 12, 2024
Last Updated
February 12, 2025
NCT07489378
NCT07181681
NCT06257264
NCT06423326
NCT07360314
NCT07204340
Lead Sponsor
PureTech
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions